OR-RADISYS
21.5.2020 09:24:06 CEST | Business Wire | Press release
Radisys® Corporation , a global leader of open telecom solutions, today introduced Connect Open Broadband , a carrier-grade, Tier 1 network-hardened, scalable and secure software-defined Passive Optical Network (PON) distribution based on open standards and web-scale architecture to drive rapid innovation and economies of scale. The disaggregated PON solution gives Communications Service Providers (CSPs) deployment flexibility, scalable network growth, and increased service agility with optimized CapEx and OpEx.
News Highlights
- The demand for high-speed broadband services such as internet, video calling and conferencing, and IPTV has created massive growth in network data usage like never before. As such, CSPs’ networks are increasingly overburdened. Service providers need to optimize their networks to scale service delivery efficiently, while maximizing the opportunity to deliver innovation at a rapid pace.
- Radisys’ Connect Open Broadband offers an intelligent, scalable and secure software-defined PON distribution based on the Open Networking Foundation’s (ONF) SEBA reference platform and enhanced with Radisys innovation. This architecture allows for a seamless introduction of the Broadband Forum’s OB-BAA architecture by conforming to the standard YANG models with the Northbound Interface (NBI).
- The solution disaggregates software from the underlying hardware with open interfaces, enabling faster product innovation cycles. The hardware agnostic solution enables service providers to leverage white-box optical line terminals (OLTs) from an interoperable multi-vendor ecosystem for flexible deployable options.
- Connect Open Broadband, built on cloud-native microservices architecture, allows for the addition of new network functions on demand and delivers a path to automated and simplified network operation. The programmability, automation and deeper network visibility further enables better fault detection, faster service delivery and future-proof network expansions.
- The solution is access network (GPON, XGS-PON, NG-PON2) agnostic and offers flexible deployment options.
“In the digital era where high-bandwidth services and pervasive connectivity are required to meet subscriber expectations, service providers are rethinking how they build their networks to meet demand with optimal performance and value,” said Harris Razak, senior vice president of Broadband Access, Radisys. “Connect Open Broadband is a commercially ready, network-hardened solution that allows service providers to enable rapid innovation through disaggregation and to bring new services to market faster.”
“Radisys has been a Partner Member of ONF for many years and has been one of the most active supply chain members working directly with our operator partners. Radisys has helped drive ONF open reference designs and open source platforms and is among the first to commercialize solutions based on ONF platforms,” said Guru Parulkar, Executive Director, ONF. “Radisys’ Connect Open Broadband combines open architectures, software innovation, and white-box hardware to facilitate service agility.”
“Broadband service providers face increased pressure to deliver innovative services to compete with OTT providers,” said Simon Stanley, Analyst at Large, Heavy Reading. “Open, disaggregated solutions give service providers the flexibility to select best-in-class network elements from a number of vendors in order to intelligently scale their networks and deliver the services their customers demand in a cost-effective manner.”
Resources:
- Solution Brief: Connect Open Broadband Access
- Heavy Reading Webinar: Supercharge Your Fiber Broadband Service, May 21 at 12 pm ET
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com .
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005223/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
